Skip to content

TruSight Oncology 500 Portfolio

TruSight Oncology 500 Assay

Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue with the added flexibility of automation-friendly kits.

TruSight Oncology 500 High-Throughput Assay

Batch up to 192 samples at a time while using the same panel content and tissue input type as the TruSight Oncology 500 assay.

TruSight Oncology 500 ctDNA Assay

Analyze liquid biopsies (blood) to assess circulating tumor DNA (ctDNA) with similar DNA panel content as the TruSight Oncology 500 assay.

Pan-Cancer Biomarkers

Detection of currently relevant DNA & RNA variants for multiple types of cancer.
Some key biomarkers include:
Pan-Cancer Biomarkers      NTRK1        NTRK2        NTRK3        MSI        TMB
Lung Melanoma Colon Ovarian Breast Gastric Bladder Sarcoma
AKT1 BRAF AKT1 BRAF AKT1 BRAF MSH5 ALK
ALK CTNNB1 BRAF BRCA1 AR KIT PMS2 APC
BRAF GNA11 HRAS BRCA2 BRCA1 KRAS TSC1 BRAF
DDR2 GNAQ KRAS KRAS BRCA2 MET   CDK4
EGFR KIT MET PDGFRA ERBB2 MLH1   CTNNB1
ERBB2 MAP2K1 MLH1 FOXL2 FGFR1 PDGFRA   ETV6
FGFR1 NF1 MSH2 TP53 FGFR2 TP53   EWSR1
FGFR3 NRAS MSH6   PIK3CA     FOXO1
KRAS PDGFRA NRAS   PTEN     GLI1
MAP2K1 PIK3CA PIK3CA         KJT
MET PTEN PMS2         MDM2
NRAS TP53 PTEN         MYOD1
PIK3CA   SMAD4         NAB2
PTEN   TP53         NF1
RET             PAX3
TP53             PAX7
              PDGFRA
              PDGFRB
              SDHB
              SDHC
              SMARCB1
              TFE3
              WT1

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.

A New Dawn for Comprehensive Genomic Profiling

Published results from early access program demonstrate the reproducibility and reliability of TruSight Oncology 500

Read Article
Illumina NGS Methods Guide

TruSight Oncology 500 Portfolio Resources

Enabling Scalable Comprehensive Genomic Profiling from FFPE Samples

Experts discuss why they decided to implement in-house CGP, share analytical performance data, and provide details about their end-to-end workflow.

Comprehensive Genomic Profiling (CGP) from Liquid Biopsies in Clinical Trials

Learn critical workflow and bioinformatics considerations when consolidating biomarkers testing into a panel that enables CGP from liquid biopsy samples in clinical trials.

Results from QuIP Study on Tumor Mutational Burden (TMB) Measurement

15 European centers participated in this Quality in Pathology (QuIP) study which tested inter-laboratory and inter-platform variation for gene panel vs. whole exome for reliable tissue TMB assessment.

NTRK Fusion Detection for Identification of Rare Genomic Events

NTRK fusions are rare but important biomarkers linked to response to new TRK inhibitors. Watch CMO Phil Febbo and Maude Champagne walk through these advances in fusion detection.

Have questions about our products? Connect with an Illumina representative.